PDCD1 and glioblastoma: Additionally, clinical trials are underway for anti-LAG-3 combined with anti-PD-1 mAb for glioblastoma (NCT02658981) and other cancers (NCT02460224), and the combination of anti-TIM3 and anti-PD-1 antibodies for liver cancer (NCT03680508) and several other solid tumors (NCT03744468) [4,5,6,7,8].